CASI Pharmaceuticals

Popular Searches:

Your Previous Searches:

Recently Visited Pages:

Home
Equities
Equities
View All Equities
Equities by Sector

Consumer

Energy & Resources

Financials

Healthcare

Industrials

Investment Companies

Metals & Mining

Real Estate

TMT

Pharnext

MCap

1m

Last close

EUR0.10

▲ 0.03 (42.86%)

MoneyHero

MCap

USD60m

Last close

USD2.35

▲ 0.55 (30.56%)

MGI – Media and Games Invest

MCap

EUR235m

Last close

EUR1.50

▲ 0.35 (30.21%)
Sectors
Sectors
Investment Strategy
Investment Strategy
View All

Latest
Thematics
Thematics
View All Thematics

Latest
Audiovisual
Audiovisual
View All Audiovisual

Latest

Events
About Edison
About Edison
About Edison

Careers

“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”

James Brotherton Financial Director — Tyman
Equity Research
Investor Relations
Contact us

Overview
Price performance
Financials
Research
Thematics

Edison Investment Research is terminating coverage on CASI Pharmaceuticals. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Latest Insights

Healthcare |
Update

19.08.21

CASI Pharmaceuticals — Evomela sales drive guidance upgrade

Healthcare |
Update

18.05.21

CASI Pharmaceuticals — Continuing to execute

Healthcare |
Review

06.04.21

CASI Pharmaceuticals — Continuing to advance and expand the pipeline

Healthcare |
Update

19.02.21

CASI Pharmaceuticals — Evomela sales going strong into 2021

Visit Website

Sector

Healthcare

Share Price Performance

Financials

Previously published reports can still be accessed via our website.

Update

Healthcare

16.12.19

CASI Pharmaceuticals — Evomela shows a strong launch

Update

Healthcare

29.08.19

CASI Pharmaceuticals — Evomela launch underway

Update

Healthcare

26.04.19

CASI Pharmaceuticals — CASI acquires an early stage CD38 mAb

Update

Healthcare

03.04.19

CASI Pharmaceuticals — Executing on China rollout

Update

Healthcare

10.12.18

CASI Pharmaceuticals — Evomela approved in China

Initiation

Healthcare

29.11.18

Equities

Equities by Sector

Sectors

Investment Strategy

Latest

Equity strategy and market outlook – April 2024

Equity strategy and market outlook – March 2024

Equity strategy and market outlook – February 2024

Thematics

Latest

Listed private equity – Performing a balancing act

ConsumerWatch – At least someone loves me

MediaWatch – Rinse and repeat

Audiovisual

Latest

Checkit – executive interview

International Public Partnerships – executive interview

Unlocking US capital: Strategies for non-US-listed businesses

About Edison

About Edison

Careers

CASI Pharmaceuticals (US: CASI)

Latest Insights

CASI Pharmaceuticals — Evomela sales drive guidance upgrade

CASI Pharmaceuticals — Continuing to execute

CASI Pharmaceuticals — Continuing to advance and expand the pipeline

CASI Pharmaceuticals — Evomela sales going strong into 2021

Sector

Share Price Performance

Financials

CASI Pharmaceuticals — Evomela shows a strong launch

CASI Pharmaceuticals — Evomela launch underway

CASI Pharmaceuticals — CASI acquires an early stage CD38 mAb

CASI Pharmaceuticals — Executing on China rollout

CASI Pharmaceuticals — Evomela approved in China

CASI Pharmaceuticals — Riding the wave of Chinese reform